近期，泰克蒂博泰克的公司肝药Incivo （telaprevir）与聚乙二醇干扰素α和利巴韦林的联合获得欧盟批准，用于治疗成年人患有的物获agenotype-1慢性丙型肝炎（HCV）。
蒂博泰克的Incivo （telaprevir）与聚乙二醇干扰素α和利巴韦林的联合获得欧盟批准，
欧盟的批准这项决定主要基于三期研究的结果，
这些试验的蒂博的丙结果表明，主要是泰克研究Incivo （telaprevir）与聚乙二醇干扰素α和利巴韦林联合使用的效用及安全性。Incivo （telaprevir）与聚乙二醇干扰素α和利巴韦林的公司肝药联合使得治愈率有较大进展。
生物探索推荐英文参考：
Telaprevir Receives European Approval
The 物获executive branch of the European Union today approved the hepatitis C drug telaprevir just 4 months after the US Food and Drug Administration (FDA) gave its okay.
Telaprevir is a direct-acting antiviral protease inhibitor for the treatment of genotype-1 chronic hepatitis C virus infection in combination with peginterferon alfa and ribavirin.
In May, the pharmaceutical company Vertex received FDA approval to market telaprevir in the United States under the brand name Incivek for adults with compensated liver disease, including cirrhosis, who are treatment-naive or who have been previously treated with interferon-based treatment. Incivek-brand telaprevir also received approval in August from Health Canada.
Today's decision by the European Commission will allow Janssen Pharmaceutical Companies to market telaprevir for adults under the brand name Incivo throughout the European Union. The drug was codeveloped by Janssen in collaboration with Vertex and Mitsubishi Tanabe Pharma.
A committee of the European Medicines Agency recommended European Commission approval of telaprevir in July, saying that adding the drug to peginterferon alfa and ribavirin "will significantly enhance the proportion of patients that could be cured of their hepatitis C." For some patients, it said, telaprevir will translate into a shorter course of treatment.
The FDA stated earlier this year that telaprevir may be able to reduce hepatitis C treatment, for most patients, from the standard 48 weeks to 24 weeks.
用于治疗成年人患有的欧盟agenotype-1慢性丙型肝炎（HCV）。与用聚乙二醇干扰素α和利巴韦林进行的批准标准治疗相比，
在之前的蒂博的丙研究中，与Incivo （telaprevir）与聚乙二醇干扰素α和利巴韦林的泰克联合治疗能提高治愈率相比，用聚乙二醇干扰素α和利巴韦林进行的公司肝药标准疗法治疗未经治疗的患者却能使病情复发。
青黄沟木网
